Griselle Villar Ledesma
Medical · Corona, NYNPI 1255710240
Payments from drug & device makers
Across 277 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$839
- Mannkind Corporation$690
- Amgen$564
- Cequr Corporation$411
- Amneal Pharmaceuticals LLC$403
- Corcept Therapeutics$389
- plus $4K from 33 others
What the payments were for
- Food & beverage$6,56696%
- Education$2594%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $839 |
| Mannkind Corporation | 26 | $690 |
| Amgen(2 entities) | 25 | $564 |
| Cequr Corporation | 3 | $411 |
| Amneal Pharmaceuticals LLC | 27 | $403 |
| Corcept Therapeutics | 10 | $389 |
| Boehringer Ingelheim | 15 | $364 |
| Lilly USA, LLC | 15 | $331 |
| Abbott | 11 | $269 |
| Seagen Inc. | 3 | $252 |
| Medtronic | 11 | $239 |
| Ascendis Pharma Endocrinology Inc | 4 | $204 |
| Insulet Corporation | 9 | $193 |
| Bayer | 6 | $189 |
| Amarin Pharma, Inc. | 9 | $153 |
| Sanofi-aventis U.S. LLC | 7 | $151 |
| Vanda Pharmaceuticals Inc. | 5 | $131 |
| IBSA Pharma Inc. | 7 | $129 |
| Merck | 7 | $121 |
| Xeris Pharmaceuticals, Inc. | 4 | $92 |
| Chiesi USA, Inc. | 3 | $81 |
| Tandem Diabetes Care, Inc. | 3 | $68 |
| Amryt Pharma Holdings Ltd | 2 | $58 |
| Radius Health, Inc. | 3 | $55 |
| Eisai Inc. | 2 | $50 |
| Averitas Pharma Inc. | 2 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| BD | 2 | $39 |
| Vistapharm, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Pfizer | 2 | $30 |
| Intra-sana Laboratories | 1 | $29 |
| Dexcom, Inc. | 1 | $27 |
| Zealand Pharma US, Inc. | 1 | $24 |
| Rhythm Pharmaceuticals, Inc. | 1 | $22 |
| Lifescan, Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| AstraZeneca | 1 | $17 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$350
- Korlym$161
- EVENITY$125
- Yorvipath$125
- AFREZZA$108
How this compares
$6,826 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $64,178 |
| TrulicityDulaglutide | 28 | $29,411 |
| MounjaroTirzepatide | 19 | $22,585 |
| JardianceEmpagliflozin | 21 | $18,147 |
| FarxigaDapagliflozin Propanediol | 23 | $16,740 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $15,905 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $14,255 |
| JanuviaSitagliptin Phosphate | 13 | $9,373 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 29 | $9,241 |
| Novolog FlexpenInsulin Aspart | 52 | $7,959 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 22 | $6,646 |
| VascepaIcosapent Ethyl | 11 | $4,287 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $3,031 |
| SynthroidLevothyroxine Sodium | 23 | $2,322 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 28 | $2,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $839 | $64,17857 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $331 | $51,99647 claims |
| MerckJanumet, Januvia | $121 | $25,27830 claims |
| Boehringer IngelheimJardiance | $364 | $18,14721 claims |
| AstraZenecaFarxiga | $17 | $16,74023 claims |
| AbbVieSynthroid | $13 | $2,32223 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $403 | $98287 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.
Other medical in Corona
- Luis HammerCorona$14K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.